rational
cardiac
stem
cellderiv
exosom
demonstr
promot
cardiac
regener
follow
myocardi
infarct
preclin
studi
recent
studi
use
intramyocardi
inject
order
concentr
exosom
infarct
though
effect
research
set
method
clinic
appeal
due
invas
natur
propos
use
target
peptid
cardiac
home
peptid
chp
target
intravenouslyinfus
exosom
infarct
heart
method
exosom
conjug
chp
dopenh
linker
ex
vivo
target
analyz
incub
organ
section
chp
exosom
analyz
fluoresc
microscopi
vitro
assay
perform
neonat
rat
cardiomyocyt
cell
anim
studi
util
ischemiareperfus
rat
model
anim
treat
either
salin
scrambl
peptid
exosom
chp
exosom
h
surgeri
echocardiographi
perform
h
surgeri
surgeri
anim
sacrif
organ
collect
analysi
result
conjug
exosom
chp
demonstr
increas
retent
exosom
within
heart
section
ex
vivo
vitro
neonat
rat
cardiomyocyt
vitro
studi
show
improv
viabil
reduc
apoptosi
increas
exosom
uptak
use
chpxo
use
anim
model
ischemiareperfus
injuri
measur
heart
function
infarct
size
cellular
prolifer
angiogenesi
improv
outcom
chp
exosom
conclus
result
demonstr
novel
method
increas
deliveri
treatment
myocardi
infarct
target
exosom
infarct
heart
signific
improv
outcom
reduc
fibrosi
scar
size
increas
cellular
prolifer
angiogenesi
due
limit
regener
cardiomyocyt
stem
cell
premier
choic
promot
myocardi
regener
numer
clinic
trialssuch
apollo
ccure
caduceu
scipio
demonstr
cardiac
regen
potenti
ivyspr
intern
publish
variou
stem
cell
subsequ
studi
demonstr
lack
long
term
stem
cell
engraft
differenti
major
benefici
effect
stem
cell
come
secretom
includ
extracellular
microvesicl
emv
three
known
type
emv
apoptot
bodi
microvesicl
exosom
compos
lipid
bilay
yet
exosom
differenti
form
within
endosom
act
mediat
paracrin
signal
exosom
protect
carri
protein
mirna
cell
exosom
produc
cardiospherederiv
stem
cell
cdc
proven
induc
myocardi
regener
via
transport
mirna
myocardium
despit
efficaci
exosom
method
deliveri
heart
less
ideal
previou
studi
use
intracoronari
intramyocardi
inject
intramyocardi
deliveri
effect
two
intramyocardi
inject
accept
anim
studi
clinic
set
much
seriou
procedur
requir
physician
perform
catheter
procedur
ideal
exosom
would
deliv
intraven
shown
major
intraven
inject
exosom
absorb
within
liver
offset
nonspecif
deliveri
previou
studi
util
dosag
approxim
ten
time
greater
use
intramyocardi
studi
shown
tabl
studi
creat
infarcttarget
exosom
use
cardiac
home
peptid
chp
increas
efficaci
decreas
effect
dose
intraven
deliv
exosom
exosom
isol
previous
describ
use
ultrafiltr
briefli
cell
grown
confluenc
fetal
bovin
serum
fb
corn
corn
ny
supplement
iscov
modifi
dulbecco
medium
gibco
waltham
media
chang
media
without
fb
media
condit
cell
extend
period
time
day
cardiospherederiv
cell
cdc
day
milliporesigma
st
loui
mo
use
ex
vivo
target
experi
experi
use
cdcxo
condit
media
filter
steril
filter
remov
cell
particul
apoptot
bodi
concentr
buffer
exchang
pb
use
kda
ultrafiltr
column
emd
millipor
billerica
size
concentr
isol
exosom
ascertain
use
nanoparticl
track
analysi
nta
nanosight
malvern
worcestershir
unit
kingdom
electron
microscopi
exosom
stain
use
uranyl
oxal
follow
previous
describ
protocol
sdspage
western
blot
perform
use
protein
gradient
gel
biorad
hercul
ca
transfer
use
wet
transfer
method
exosom
tag
peptid
shown
target
infarct
heart
known
cardiac
home
peptid
chp
cstsmlkac
scrambl
peptid
scr
csktalsmc
chemic
ident
random
intern
sequenc
peptid
synthes
genscript
piscataway
nj
peptid
conjug
exosom
use
modif
previous
describ
method
dopenh
dioleoylphosphatidylethanolamin
nhydroxysuccinimid
nof
america
white
plain
ny
peptid
combin
molar
excess
peptid
allow
react
h
form
dopepeptid
dopepeptid
incub
exosom
lipid
exosom
ratio
ie
molecul
dopepeptid
exosom
see
supplementari
method
rational
illustr
conjug
reaction
shown
figur
follow
label
lipophil
dye
dii
perchlor
thermofish
scientif
waltham
dir
nine
iodid
thermofish
scientif
waltham
excess
reagent
remov
use
kda
ultrafiltr
spin
filter
adjust
final
concentr
use
pb
exosom
deriv
cell
tag
chp
peptid
label
dii
exosom
incub
fix
cryosect
rat
organ
h
follow
min
wash
pb
dapi
label
visual
entir
organ
imag
stitch
use
imagej
avoid
animaltoanim
variat
exosom
bind
infarct
heart
section
organ
acquir
singl
rat
ex
vivo
target
assay
imag
acquir
use
exposur
time
allow
use
quantit
measur
indic
weight
list
paper
acquir
sourc
fresh
neonat
rat
cardiomyocyt
nrcm
isol
previous
describ
cell
cultur
day
cultur
slide
stress
cell
serumfre
medium
contain
either
chpxo
scrxo
pb
ad
cell
incub
h
prior
fixat
analysi
cell
stain
alphasarcomer
actinin
label
muscl
fiber
cardiomyocyt
determin
viabil
cell
posit
contain
dapilabel
nuclei
round
count
viabl
cell
simul
ischem
injuri
cell
sigma
aldrich
st
loui
mo
incub
h
follow
h
treatment
either
scrxo
chpxo
cell
apoptosi
assess
tunel
stain
procedur
perform
studi
approv
north
carolina
state
univers
institut
anim
care
use
committe
conduct
within
aaalac
internationalaccredit
facil
weekold
femal
sd
rat
charl
river
laboratori
worcest
util
rat
clinic
healthi
prior
studi
free
recogn
pathogen
rat
coronaviru
rat
parvoviru
rat
minut
viru
kilham
rat
viru
toolan
viru
rat
theiloviru
sendai
viru
pneumonia
viru
mice
mycoplasma
pulmoni
pneumocisti
carinii
rat
hous
static
microisol
cage
directcontact
corn
cob
bed
anderson
inc
maume
oh
room
maintain
control
environment
condit
h
light
dark
cycl
temperatur
rat
provid
standard
rodent
chow
formula
labdiet
st
loui
mo
ad
libitum
provid
continu
access
water
use
suspend
water
bottl
thirti
femal
sd
rat
anesthet
intraperiton
administr
anesthet
combin
mixtur
ketamin
xylazin
depth
anesthesia
test
perform
withdraw
reflex
test
least
toe
absenc
reflex
confirm
suffici
anesthesia
artifici
ventil
rodent
ventil
small
anim
ventil
cwe
inc
ardmor
pa
ischemiareperfus
surgic
oper
perform
left
coronari
arteri
lad
ligat
use
cm
length
silk
sutur
mm
open
th
intercost
space
plain
knot
tie
left
insitu
min
ischemia
confirm
rat
appear
discolor
heart
surfac
min
ligatur
releas
reperfus
verifi
redden
previous
discolor
area
heart
muscl
chest
close
neg
pressur
rat
extub
observ
approxim
min
abl
move
echocardiogram
acquir
h
day
ischemiareperfus
surgeri
philip
ultrasound
system
transduc
philip
amsterdam
netherland
individu
perform
echocardiographi
analysi
blind
treatment
anim
receiv
anim
anesthet
isofluran
echocardiographi
eject
fraction
measur
use
simpson
method
use
bmode
imag
measur
ventricular
volum
anim
transfer
cage
follow
observ
period
rat
treat
pb
scrambl
peptid
exosom
scrxo
chp
target
exosom
chpxo
via
tail
vein
inject
three
group
inject
volum
scrxoand
chpxotreat
group
treatment
scrxo
chpxo
pb
respect
anim
group
distribut
equal
cage
random
sequenc
treatment
predetermin
cyclic
manner
keep
group
size
anim
randomli
drawn
cage
assign
one
three
treatment
group
predict
base
previou
studi
anim
die
due
complic
shortli
surgeri
anim
die
follow
deliveri
treatment
due
sever
death
anim
assign
one
group
predetermin
sequenc
adjust
toward
end
studi
rebal
group
group
sequenc
determin
individu
present
surgeri
echocardiographi
ex
vivo
imag
anim
sacrif
h
follow
inject
anim
mortal
rate
studi
rat
specimen
sacrif
day
immunohistochemistri
ihc
heart
section
fix
paraformaldehyd
solut
permeabil
saponin
sigmaaldrich
st
loui
mo
block
use
protein
block
solut
dako
glostrup
denmark
primari
antibodi
incub
overnight
subsequ
secondari
antibodi
room
temperatur
h
sampl
treat
dapi
lifetech
carlsbad
ca
mount
prolong
gold
mount
media
lifetech
carlsbad
ca
imag
acquir
use
olympu
fluoresc
microscop
zeiss
confoc
microscop
imag
process
analysi
perform
use
imagej
analyz
dii
uptak
nuclear
stain
subtract
prior
measur
avoid
detect
label
figur
display
mean
standard
deviat
error
bar
statist
analysi
perform
use
graphpad
prism
graphpad
softwar
inc
la
jolla
ca
analys
twoway
anova
tukey
multipl
comparison
test
use
analyz
data
p
consid
signific
indic
figur
asterisk
technic
replic
acquir
portion
follow
echocardiogram
three
technic
replic
imag
sequenc
acquir
analyz
microscopi
least
two
section
imag
specimen
high
magnif
imag
whole
heart
least
three
imag
acquir
analyz
determin
proper
isol
hcdcxo
without
cellular
contamin
exosom
character
use
western
blot
nta
tem
western
blot
confirm
exosom
presenc
exosom
marker
lack
cellular
contamin
verifi
use
nuclear
protein
pcna
figur
exosom
size
confirm
nm
via
nta
tem
imag
confirm
round
morpholog
exosom
figur
possibl
directli
determin
exosom
label
nta
abl
differenti
label
unlabel
exosom
figur
instead
use
indirect
method
test
whether
addit
target
peptid
would
increas
retent
exosom
exosom
incub
slide
section
rat
kidney
liver
lung
spleen
infarct
heart
exosom
track
quantifi
dii
label
shown
exosom
demonstr
innat
home
abil
base
upon
fluoresc
integr
densiti
taken
seri
imag
chptag
exosom
exhibit
improv
target
infarct
heart
figur
organ
liver
show
decreas
signal
chpxo
compar
scrxo
data
indic
chp
conjug
abl
increas
ontarget
decreas
offtarget
deliveri
system
administ
exosom
prior
carri
studi
anim
model
target
exosom
test
nrcm
cultur
vitro
order
stress
nrcm
medium
switch
serumfre
medium
exosom
administ
well
cultur
slide
overal
viabil
nrcm
analyz
count
viabl
actininposit
cell
result
count
indic
chpxo
group
increas
viabl
nrcm
compar
pb
group
figur
qualit
analysi
diilabel
exosom
show
uptak
exosom
whether
tag
scrambl
chp
peptid
though
chptag
group
signific
increas
retent
also
confirm
chp
peptid
nontox
cardiomyocyt
expos
cardiac
cell
simul
infarct
hydrogen
peroxid
demonstr
chpxo
reduc
number
apoptot
cell
compar
scrxo
h
recoveri
period
follow
ischemiareperfus
injuri
eject
fraction
anim
indistinguish
group
indic
similar
degre
initi
injuri
anim
given
day
treatment
take
effect
repair
myocardi
damag
heart
function
measur
echocardiogram
tissu
collect
histolog
analysi
echocardiographi
result
demonstr
chpxo
treatment
result
increas
heart
function
group
figur
cardiac
fibrosi
contribut
reduct
cardiac
function
masson
trichrom
stain
use
measur
size
fibrot
region
upon
measur
imag
inject
chpxo
led
decreas
infarct
tissu
area
consequ
increas
viabl
tissu
atrisk
region
figur
order
determin
cellular
respons
chpxo
therapi
immunohistochemistri
perform
sever
target
distinguish
cardiomyocyt
cell
use
costain
immunofluoresc
imag
show
increas
cardiomyocyt
prolifer
follow
chpxo
treatment
figur
angiogenesi
measur
imag
von
willebrand
factor
vwf
show
signific
increas
chpxo
treatment
figur
exosom
human
origin
neg
effect
immun
respons
possibl
test
tcell
stain
differ
group
figur
long
period
dormanc
sinc
discoveri
exosom
research
begun
understand
valu
exosom
import
celltocel
signal
exosom
secret
cardiospherederiv
stem
cell
shown
promot
cardiac
regener
indic
benefici
effect
exosom
due
abil
shuttl
mirna
cell
cdcxo
contain
numer
mirna
particular
shown
benefici
effect
injur
myocardium
reduc
myocardi
apoptosi
modul
express
program
cell
death
fasl
akt
pathway
repress
receptorassoci
tumor
necrosi
factor
tnf
receptorassoci
factor
reduc
activ
nuclear
factor
effect
mirna
appear
result
singl
mirna
rather
effect
depend
upon
multipl
mirna
work
tandem
combin
result
signific
reduct
mitogenassoci
kinas
phosphoryl
mapk
mirna
requir
exact
match
target
mrna
mirna
repress
mani
differ
protein
coexpress
inhibit
lead
multipl
interact
alter
overlap
portion
pathway
modul
mani
possibl
outcom
mirna
modul
demonstr
chpxo
promot
cardiac
repair
reduc
scar
size
figur
increas
cardiac
prolifer
figur
increas
angiogenesi
figur
nanoscal
size
exosom
dichotom
effect
therapeut
potenti
exosom
small
size
allow
exosom
travers
capillari
bed
lung
tissu
trap
cell
larger
particl
simultan
reduc
rate
extravas
exosom
hypothes
target
tissu
deliv
intraven
larg
amount
exosom
shown
accumul
target
organ
liver
thu
far
studi
definit
shown
side
effect
excess
exosom
inject
though
one
studi
report
death
one
anim
receiv
larg
dose
intraven
exosom
possibl
due
pulmonari
embol
drug
target
primarili
studi
mean
reduc
neg
offtarget
effect
chemotherapeut
drug
although
increas
interest
drug
target
cardiac
regener
follow
myocardi
infarct
myocardium
undergo
sever
chang
exploit
target
one
chang
increas
vascular
permeabl
analog
enhanc
permeabl
retent
epr
effect
cancer
allow
increas
extravas
liposom
chang
protein
express
well
exposur
normal
intracellular
protein
myosin
util
target
due
high
specif
antibodi
antibodi
fragment
target
molecul
choic
recent
studi
also
show
platelet
membran
could
util
target
cell
infarct
heart
recent
develop
phage
display
yield
mani
new
target
molecul
chp
though
exact
mechan
chp
interact
myocardium
unknown
conjug
exosom
amplifi
regen
effect
exosom
limit
studi
mechan
underli
regen
properti
exosom
fulli
elucid
nevertheless
recent
studi
group
other
demonstr
proangiogen
promyogen
antiapoptot
antiinflammatori
role
stem
cell
secretom
result
demonstr
effect
method
increas
potenc
cdcxo
cardiac
regener
use
cardiac
home
peptid
use
dopenh
allow
peptid
molecul
conjug
exosom
possibl
membranebas
nanoparticl
target
exosom
result
increas
uptak
cardiomyocyt
vitro
well
increas
function
recoveri
anim
model
reduc
fibrosi
induc
cardiomyocyt
prolifer
increas
angiogenesi
use
cardiactarget
exosom
repres
promis
method
treatment
myocardi
infarct
cardiac
home
peptid
cdc
cardiospherederiv
cell
dope
dioleoylphosphatidylethanolamin
emv
extracellular
microvesicl
ir
ischemiareperfus
nh
nhydroxysucci
supplementari
figur
tabl
http
